Science

The BioCentury Show

by BioCentury

Share this ranking Is this your show? Claim it

Listen on Apple Podcasts RSS feed

Chart positions today · Germany

Not on the Germany charts we track today.

If you like The BioCentury Show, try…

The Genetics Podcast

Also in Science

Small Biotechs; Big Decisions

Latest episodes

Ep. 122 - Tigermed's Britney Winterberger's take on running trials in the U.S. and China

October 21, 2026 · 30 min

Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored edition of The…
Ep. 121 - Arrowhead’s Chris Anzalone on the future of RNAi

October 17, 2026 · 37 min

Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show, Arrowhead Chairman…
Ep. 120 - Canaan’s Julie Grant on building biotechs in white spaces

October 2, 2026 · 39 min

Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5…
Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile

September 18, 2026 · 35 min

On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing…
Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets

September 4, 2026 · 32 min

On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the…

Show 7 more episodesShow fewer episodes

Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient

August 21, 2026 · 30 min

The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative…
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance

August 7, 2026 · 33 min

Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an…
Ep. 115 - Initiate's Owens on what it takes to be AI-native

July 23, 2026 · 40 min

As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show, Owens…
Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

July 10, 2026 · 42 min

Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized…
Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking

June 25, 2026 · 35 min

Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank Jiang, EVP and…
Ep. 112 - Chris Arendt on rebuilding Takeda for AI

June 18, 2026 · 40 min

Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat…
Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner

June 12, 2026 · 37 min

ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show…

Full episode archive on Apple Podcasts →

About the show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.